Waylis Therap Company Profile

What is the competitive landscape for WAYLIS THERAP

WAYLIS THERAP has fifteen approved drugs.

There is one US patent protecting WAYLIS THERAP drugs.

There are twenty-four patent family members on WAYLIS THERAP drugs in fourteen countries and eight supplementary protection certificates in five countries.

Summary for Waylis Therap

International Patents:	24
US Patents:	1
Tradenames:	15
Ingredients:	14
NDAs:	15

Drugs and US Patents for Waylis Therap

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Waylis Therap	DROXIA	hydroxyurea	CAPSULE;ORAL	016295-002	Feb 25, 1998		DISCN	Yes	No
Waylis Therap	COREG	carvedilol	TABLET;ORAL	020297-002	Sep 14, 1995	AB	RX	Yes	Yes
Waylis Therap	LUNESTA	eszopiclone	TABLET;ORAL	021476-003	Dec 15, 2004	AB	RX	Yes	Yes

Expired US Patents for Waylis Therap

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Waylis Therap	HYDREA	hydroxyurea	CAPSULE;ORAL	016295-001	Approved Prior to Jan 1, 1982	3,968,249
Waylis Therap	VALIUM	diazepam	TABLET;ORAL	013263-004	Approved Prior to Jan 1, 1982	4,316,897
Waylis Therap	JALYN	dutasteride; tamsulosin hydrochloride	CAPSULE;ORAL	022460-001	Jun 14, 2010	5,846,976

Paragraph IV (Patent) Challenges for WAYLIS THERAP drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Capsules	0.5 mg		2007-10-29
	Capsules	1 g		2008-11-10
	Extended-release Capsules	10 mg and 20 mg		2008-03-18
	Extended-release Capsules	80 mg		2007-11-19
	Capsule	0.5 mg/0.4 mg		2010-10-26
	Tablets	1 mg, 2 mg and 3 mg		2008-12-15
	Extended-release Capsules	40 mg		2007-12-21

International Patents for Waylis Therap Drugs

Country	Patent Number	Estimated Expiration
Japan	2005506336
South Korea	20100063825
Canada	2463134

Supplementary Protection Certificates for Waylis Therap Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0719278	23/2003	Austria		PRODUCT NAME: DUTASTERIDE, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SOLVATES; NAT. REGISTRATION NO/DATE: 1-24844, 1-24845 20030217; FIRST REGISTRATION: SE 17871, 17872 20020719
0719278	SPC/GB03/018	United Kingdom		PRODUCT NAME: DUTASTERIDE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SOLVATE.; REGISTERED: SE 17871 20020719; SE 17872 20020719; UK PL 19494/0005 20030117; UK PL 19494/0006 20030117
0268956	1999C0030	Belgium		PRODUCT NAME: RABEPRAZOLE SODIUM; NAT. REGISTRATION NO/DATE: 5532 IE 1 F 3 19990201; FIRST REGISTRATION: GB 10555/0010 19980508

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Waylis Therap

Last updated: April 23, 2026

Waylis Therap: Competitive Landscape, Market Position, Strengths, and Strategic Insights

Waylis Therap operates in a high-friction sector where commercial advantage is determined by (1) patent defensibility around key assets, (2) distribution access and formulary placement, (3) evidence density from clinical trials and real-world studies, and (4) supply-chain reliability. A precise competitive landscape requires verified product, pipeline, geography, and IP facts; none are provided in the input. Without those facts, a complete, accurate market-position and competitive-strength analysis cannot be produced.

What is Waylis Therap’s market position by product, geography, and channel?

No validated data is provided for:

• Sold products (brand/generic), indications, labels
• Revenues, market share, or pricing
• Licensed geographies and distribution partners
• Channel mix (hospital, retail, tender) or payer coverage

What are Waylis Therap’s competitive strengths that translate into defensible performance?

No verified information is provided for:

• Patent portfolio (granted/pending, jurisdictions, expiry dates)
• Clinical-stage assets (phase, endpoints, readouts)
• Manufacturing footprint (sites, cGMP status, capacity)
• Safety/quality history and batch failure rates
• Pharmacovigilance system maturity and audit outcomes

Who are Waylis Therap’s closest competitors, and where do they outmatch or underperform?

No competition set can be constructed without:

• Therapeutic area(s) Waylis targets
• Specific molecules and dosage forms
• Claims, effectiveness benchmarks, and pricing references
• Country-level reimbursement and tender dynamics

What strategic moves create near-term leverage and longer-term defensibility?

No asset-level basis is provided to recommend:

• Evidence-generation strategy (phase extension vs. RWE)
• IP strategy (secondary patents, formulation, method-of-use)
• Commercial strategy (payer evidence packages, tender bidding)
• Launch sequencing (indication expansion, life-cycle management)

Key Takeaways

• A complete competitive landscape for Waylis Therap cannot be generated from the provided input because essential facts on products, pipeline, and IP are missing.
• No accurate market-position statement can be issued without verified geography, indications, and commercial metrics.
• No defensible competitive-strength assessment can be produced without validated IP and clinical data.
• No competitor mapping can be completed without Waylis’s therapeutic focus and asset list.

FAQs

1. Can you rank Waylis Therap among competitors without product or pipeline data?
   No. Competitive ranking depends on assets, geographies, and evidence levels.

2. What data is required to assess patent defensibility for Waylis Therap?
   Patent families, jurisdictions, claim scope, priority dates, and remaining term for lead assets.

3. How is “market position” typically measured in this sector?
   It is measured via revenue, share, pricing, reimbursement coverage, and channel penetration by geography and indication.

4. What constitutes “competitive strength” beyond clinical efficacy?
   It includes formulary access, tender wins, manufacturing reliability, safety performance, and evidence density for payers.

5. What strategic insights are feasible without knowing the lead therapeutic areas?
   Only generic statements, which do not meet the requirement for an actionable, accurate competitive analysis.

References

[1] Not provided.